RENAL CELL CARCINOMA

This early-phase study tested the safety of combining two drugs—pembrolizumab (an immunotherapy) and AMG386 (which targets blood vessel growth)—in 62 people with advanced solid tumors like melanoma, ovarian, renal, or colorectal cancer. The main goals were to find the safest dose…

This study tested a combination of two experimental treatments for people with advanced kidney cancer that cannot be removed by surgery. The first is Pexa-Vec, a modified virus designed to infect and destroy cancer cells while also boosting the immune system. The second is cemipl…

This early-phase study tested an experimental drug called APX005M added to two standard immunotherapies (nivolumab and ipilimumab) in 26 people with advanced melanoma or kidney cancer who had not received prior immune therapy. The main goals were to check safety and find the best…

This study tested a new drug called XTX202 in 95 people with advanced solid tumors that had not responded to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The trial is now complete.

This study tested whether adding an immunotherapy drug (nivolumab) to a targeted therapy (tivozanib) helps people with advanced kidney cancer live longer without their cancer growing. The trial included 343 adults whose cancer had worsened after one or two prior treatments, inclu…

This early-phase study tested a new drug, HBM1020, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The drug was given by IV every three weeks. Because this is a Phase 1 trial, i…

This study looked at how safe and effective the drug Cabozantinib is for people aged 70 and older with advanced kidney cancer. Researchers tracked side effects and tumor response in 100 participants. The goal was to see if this treatment works well in older patients who have alre…

This study tested an experimental drug called BMS-986016 (anti-LAG-3) alone or combined with nivolumab in people with advanced solid tumors that had spread or couldn't be removed by surgery. It included several cancer types like lung, stomach, liver, kidney, bladder, head and nec…

This early-phase study tested a new drug called gevokizumab alongside standard cancer treatments in 167 adults with advanced colorectal, stomach, or kidney cancer that had spread. The goal was to find a safe and active dose and see if the combination could help control the diseas…

This Phase 3 trial tested whether the immunotherapy drug pembrolizumab (Keytruda) could help prevent kidney cancer from coming back after surgery. Nearly 1,000 participants who had their kidney removed due to renal cell carcinoma received either pembrolizumab or a placebo. The st…

This study tested a new way to do stem cell transplants in 23 children with cancers that came back or didn't respond to treatment. The method removes certain immune cells from the donor's stem cells to help the child's body recover faster and fight infections better. The goal was…

This phase 3 trial tested whether combining the immunotherapy drug pembrolizumab with the targeted drug axitinib works better than the standard drug sunitinib alone for people with advanced kidney cancer. Over 860 patients took part. The combination helped patients live longer an…

This study tested a personalized vaccine made from a patient's own tumor cells mixed with immune cells from a healthy donor. The goal was to see if the vaccine is safe and can help the immune system attack advanced kidney cancer. Forty people with stage IV kidney cancer took part…

This study tested a combination of two drugs, pembrolizumab and lenvatinib, in 160 people with a rare type of advanced kidney cancer (non-clear cell renal cell carcinoma) that had not been treated before. The goal was to see if the drugs could shrink tumors. The study found that …

This study tested giving the cancer drug nivolumab as a shot under the skin (instead of through an IV) to people with advanced cancers like lung, kidney, melanoma, liver, and colorectal cancer. The main goal was to see how the drug moves in the body and to check for side effects.…

This study tested an experimental drug called BDB001 in people with advanced solid tumors (like skin, lung, or kidney cancer) that had stopped responding to standard immunotherapy. The goal was to see if BDB001 could shrink tumors or slow their growth. Only one person took part, …

This early-phase trial tested a combination of two experimental drugs, vobramitamab duocarmazine and lorigerlimab, in 31 people with advanced solid tumors like prostate, melanoma, and pancreatic cancer. The main goal was to check safety and find the right dose. Participants recei…

This study tested whether transplanting gut bacteria from people who responded well to immunotherapy could help others with advanced kidney cancer respond better. Fifty participants received either a fecal transplant or a placebo. The goal was to see if the transplant could slow …

This early-phase study tested stereotactic radiotherapy, a precise type of radiation, on 13 people with small kidney cancers (≤4 cm). The goal was to find the highest safe dose by gradually increasing the radiation in four steps. Participants were followed for up to 5 years to mo…

This study looked at whether taking the kidney cancer drug cabozantinib with a light breakfast changes how much drug gets into the body. Twelve patients with advanced kidney cancer took the drug both on an empty stomach and with a light breakfast, and researchers measured drug le…

This study tested whether a special type of MRI, called perfusion MRI, can help doctors find and diagnose kidney tumors more accurately. 75 people with kidney cancer or suspected kidney tumors took part. The goal was to see if this imaging method could predict tumor type and how …

This completed study tested whether a special type of MRI (multiparametric MRI) can accurately tell the difference between benign and malignant small kidney tumors. About 387 adults with small solid kidney masses (1.5-4 cm) were scanned before surgery or biopsy. The goal was to s…

This study looked at 98 adults who had kidney removal surgery to see which pain-blocking method works better: a paravertebral block or an external oblique intercostal block. Both are injections that numb nerves to reduce pain after surgery. The goal was to find which one leads to…

This study tested a fast-recovery program for people having minimally invasive kidney surgery (laparoscopic or robotic) to remove tumors. The goal was to see if the program could safely shorten hospital stays by at least one day. Sixty patients took part, and researchers tracked …

This completed study looked at 40,000 people with metastatic cancer who received the drug nivolumab. Researchers compared the old way of dosing (based on body weight) with a newer, simpler fixed dose. They used national health data to see if the fixed dose was just as good and mo…

This completed study created a registry of 28 patients with TFE renal cell carcinoma, a rare kidney cancer. Researchers collected medical data, tumor samples, and images to better understand the disease. The goal is to use this information to guide future research and develop mor…

This study followed 623 adults in France with advanced kidney cancer who were starting treatment with the immunotherapy drugs nivolumab (with or without ipilimumab) for the first time. Unlike a clinical trial, this was an observational study that simply tracked what happened in e…

This study looked at how lifestyle factors like obesity and muscle loss affect kidney cancer risk and survival after kidney removal. Researchers collected blood, tissue, and questionnaire data from 161 patients over up to 5 years. The goal was to understand how to personalize tre…

This completed research study collected and stored tumor tissue, blood, and urine samples from 8,000 children and young adults with kidney tumors. The goal was to help scientists study DNA changes and find biomarkers that could improve understanding of these cancers. No treatment…

This study looked at how immune checkpoint inhibitors, a type of cancer drug, might affect blood vessels and increase heart risks. Researchers measured blood vessel function and checked for related markers in 39 cancer patients before and after starting treatment. The goal was to…

This study looked at whether people with advanced cancers (melanoma, kidney, or lung cancer) receiving their first immunotherapy treatment could successfully collect small blood samples at home using a finger-prick method. The goal was to see if this approach is practical and rel…

This study explored whether small particles called exosomes, found in blood and urine, can help predict how well treatment works in people with advanced kidney cancer. Researchers followed 91 patients for 16 weeks, collecting samples and comparing them to imaging results. The goa…

This study involved 91 adults with advanced kidney cancer. Researchers collected blood and urine samples over 16 weeks to see if changes in tiny particles called exosomal miRNAs could predict whether treatment was working. The goal was to find a simple, non-invasive way to monito…

This study tested whether analyzing the DNA and RNA of a child's tumor could help doctors choose personalized treatments. It included 186 children with relapsed or hard-to-treat cancers like neuroblastoma and brain tumors. The goal was to see if this approach was feasible and saf…